Dynamic Technology Lab Private Ltd Invests $191,000 in Evolus, Inc. (NASDAQ:EOLS)

Dynamic Technology Lab Private Ltd bought a new stake in Evolus, Inc. (NASDAQ:EOLS) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 11,783 shares of the company’s stock, valued at approximately $191,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of EOLS. Price T Rowe Associates Inc. MD increased its holdings in Evolus by 4.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 39,882 shares of the company’s stock valued at $559,000 after buying an additional 1,637 shares during the period. California State Teachers Retirement System lifted its stake in Evolus by 1.6% during the first quarter. California State Teachers Retirement System now owns 48,109 shares of the company’s stock worth $674,000 after purchasing an additional 739 shares during the period. Assenagon Asset Management S.A. boosted its holdings in Evolus by 5,627.2% during the second quarter. Assenagon Asset Management S.A. now owns 947,103 shares of the company’s stock valued at $10,276,000 after purchasing an additional 930,566 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of Evolus by 24.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 181,093 shares of the company’s stock valued at $1,965,000 after purchasing an additional 35,760 shares during the period. Finally, Rhumbline Advisers lifted its position in shares of Evolus by 27.3% during the 2nd quarter. Rhumbline Advisers now owns 81,439 shares of the company’s stock worth $884,000 after buying an additional 17,442 shares during the period. 90.69% of the stock is owned by institutional investors.

Evolus Trading Down 1.3 %

Shares of EOLS opened at $13.51 on Tuesday. The stock’s fifty day simple moving average is $15.22 and its 200-day simple moving average is $13.88. The firm has a market capitalization of $855.45 million, a PE ratio of -14.85 and a beta of 1.31. Evolus, Inc. has a 12-month low of $9.38 and a 12-month high of $17.82. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58.

Wall Street Analyst Weigh In

Several analysts have weighed in on EOLS shares. HC Wainwright reaffirmed a “buy” rating and set a $27.00 price objective on shares of Evolus in a research note on Thursday, November 7th. Needham & Company LLC restated a “buy” rating and set a $22.00 target price on shares of Evolus in a report on Friday, September 13th. Cantor Fitzgerald restated an “overweight” rating on shares of Evolus in a research note on Monday, September 16th. Finally, Barclays upped their price target on shares of Evolus from $16.00 to $20.00 and gave the stock an “overweight” rating in a research report on Friday, September 13th.

Insider Buying and Selling

In other news, CFO Sandra Beaver sold 3,276 shares of the company’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $14.98, for a total value of $49,074.48. Following the completion of the sale, the chief financial officer now directly owns 148,502 shares of the company’s stock, valued at $2,224,559.96. This represents a 2.16 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 6.10% of the stock is currently owned by insiders.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.